{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-013267","form_type":"8-K","ticker":"OPRX","cik":"0001448431","company_name":"OptimizeRx Corp","filed_at":"2022-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.520310+00:00","generated_at":"2026-06-26T21:58:03.733718+00:00","sec_items":["3.02"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"OptimizeRx acquires EvinceMed assets for $2M cash and up to 240,741 shares","bullets":["Asset purchase of EvinceMed Corp.; total consideration includes $2M cash and up to 240,741 common shares.","185,185 shares issued at closing; 55,556 held back for 12 months for indemnification adjustments.","Closing expected in Q2 2022; shares issued under Section 4(a)(2) exemption.","Acquisition strengthens OptimizeRx's product offering in patient engagement technology."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-013267","json":"https://secwatch.observer/filing/0001213900-22-013267.json","markdown":"https://secwatch.observer/filing/0001213900-22-013267.md","text":"https://secwatch.observer/filing/0001213900-22-013267.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1448431/000121390022013267/0001213900-22-013267-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1448431/000121390022013267/ea157011-8k_optimizerx.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T21:58:03.733718+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}